News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
|
Followers
|
72
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2523
|
|
Created
|
02/23/14
|
Type
|
Free
|
| Moderators | |||
We have a multi-market growth strategy with a current portfolio of over 1,000,000 sq. ft. of sustainable cannabis production infrastructure in development. We are a reporting, publicly listed company with the US stock symbol: ACAN on the OTCQX marketplace.
Previously the Company entered into an agreement to purchase a 52.6 acre parcel of undeveloped land in Freetown, Massachusetts. The property is located approximately 47 miles southeast of Boston. The Company plans to develop the property as the Massachusetts Medical Cannabis Center "MMCC". Plans for the MMCC may include the construction of sustainable greenhouse cultivation, processing, and infused product facilities that will be leased or sold to Registered Marijuana Dispensaries under the Massachusetts Medical Marijuana Program.
The Company paid the seller $100,000 upon the signing of the agreement which amount will be applied toward the purchase price of $4,000,000 at the closing. Pursuant to the original agreement the closing was to take place on or before June 1, 2015. On May 6, 2015, to address site considerations before finalizing the planned development, the agreement was amended to extend the closing date to September 1, 2015. On August 27, 2015, after addressing the site considerations, the agreement was amended to extend the closing date to October 30, 2015 to provide additional time for permitting. In connection with this amendment, the Company paid the seller an additional $100,000. On October 23, 2015, the Company made an additional payment of $100,000 to extend the closing date to December 29, 2015. All payments made by the Company to the seller ($300,000) will be applied to the purchase price. On November 6th, 2015 the Company filed a Site Plan Application to the Town of Freetown Planning Department. The Planning Board will review the MMCC project on November 24th, 2015.
Source: OTC Markets http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11008156
http://americann.co/about/
AmeriCann’s goal is to serve medical cannabis patients by providing state of the art facilities designed and built to produce high quality, consistent medicine that is cultivated and processed in a controlled, secure, and sustainable environment. Our belief in sustainable cultivation and processing practices — and our responsibility towards our community and environment — is driven by the core belief that every patient should have access to safe, regulated medical cannabis.
Mr. Barton has been the managing director of a Colorado-based venture capital and private equity firm since 2006. He has extensive experience in the public and private capital markets, and has been instrumental in raising of over $800 million in equity and debt financing for emerging companies over the past decade. He earned an MBA in finance from UCLA.
Mr. Keogh offers a unique combination of firsthand experience in the cannabis industry, from licensing to operations in numerous states, and an extensive background in real estate development. He is a director of one of fifteen Provisionally Registered marijuana dispensaries in Massachusetts, a board member of the Cannabis Producers Association of New England, and an active member and invited speaker for the National Cannabis Industry Association. He received a BS in business administration from Mount St. Mary’s College.
AmeriCann’s management team has a track record of success with both private and public companies includes an unprecedented level of industry experience and depth.
Mr. Forington is the Head of Breeding and Strain Development for 303 Seeds, a cannabis genetics and seed company based in Denver, Colorado. After several years of cannabis R&D focused on the psychoactive cannabinoid compound THC, Mr. Forington shifted his focus to non-psychoactive cannabinoids including CBD, CBG, CBC and CBN. His breeding work includes the highest lab tested cannabidiol (CBD) and cannabigerol (CBG) plant specimens known in the medical cannabis market and he has received several cannabis awards.
Dr. Anderson has over 25 years’ experience in public health research design and ethics. He has been a leader in the review, funding, and commercialization of behavioral research and development, including tech-based applications for health promotion and disease prevention. Dr. Anderson was a Project Director at the National Cancer Institute (NCI;NIH) and is currently the & Human Subjects Protections Administrator for the Federally-authorized Health Media Lab Institutional Review Board (IRB) in Washington, DC. He received his Ph.D. and MPH at the University Of Minnesota School Of Public Health.
Most recently Dr. Corr managed a technical team for Syngenta responsible for providing technical advice to greenhouse facilities throughout North America. In the past he has been a faculty member at the University of Tennessee specializing in controlled-environment horticulture. Later, at the Ball Horticultural Company, he managed a research greenhouse, directed research, had responsibility for international sales and was Director of New Crop Development. In his position with Valent Biosciences he introduced a new organically-certified plant growth regulator for grape production.
Mr. Brait is a licensed attorney specializing exclusively in the legal cannabis industry since he received his law degree and has developed a through understand and knowledge of all aspects of the industry. He is the managing partner of the Denver-based Green Law Firm and a founder of the Cannabis Commodities Exchange in Colorado. He was a Distinguished Scholar at Southern Methodist University where he received his BBA in finance and BA in political science before receiving his law degree from the U. of Arizona.
Dr. Havens specializes in plant medicine and product development, with almost a decade of experience designing extraction systems, end products, conducting product and process research and creating innovative strategies for the Cannabis industry. Dr. Havens brings twenty years in alternative medicine and supplements combined with advanced training in extraction and manufacturing technology. Dr. Havens experience includes the creation of patent pending new extraction technologies and product line development for health and wellness industries.
http://americann.co/contact/
AMERICANN
Many of the best opportunities for success in the cannabis industry are in emerging markets. Getting established early in a newly regulated state could enable you to become a dominant player in your region. If you attempt to enter a market later in the licensing process, the prospects for your business may diminish significantly.
At AmeriCann, we can help you identify the most promising markets and help you navigate and obtain a valuable license. Additionally, we can provide a comprehensive set of services and the capital to help you succeed once you obtain a license.
AmeriCann, Inc. develops, owns and supports advanced medical cannabis facilities in multiple states. In an effort to advance the quality of medical cannabis and to promote greater access for patients, AmeriCann has initiated the AmeriCann Preferred Partner Program. We support local businesses that seek to serve cannabis patients in their communities.
AmeriCann does not cultivate, process, distribute or sell cannabis. Rather, we assist local partners to obtain licenses, to cultivate medicine and to provide important medicine to patients. The company provides an essential set of resources including advanced cultivation facilities, access to a team of experts and, in certain cases, working capital for our partners’ businesses. If you would like to learn more about the AmeriCann Preferred Partner Program or apply for the program, please download the Fact Sheet and complete the Preferred Partner Program Questionnaire.
Justin Anderson, managing partner of Nature’s Own Wellness Center: “The combination of services that AmeriCann provided our company – cannabis expertise in conjunction with significant capital, is unprecedented in this industry.”
He added that, “Not only did AmeriCann provide a significant loan of $1,000,000 that will help us meet the growing needs of our patients, but we have ongoing access to the company’s team of experts. This has already helped us improve the efficiency of our operations.” Sept 2014
AmeriCann partnered with Wellness Group Pharms prior to the submittal of WGP’s application in Illinois. Paul Montes, Managing Partner of WGP stated that, “Our affiliation with AmeriCann was instrumental in our success in being awarded one of the few cultivation licenses granted in an extremely competitive Illinois application process.”
Mr. Montes added, “AmeriCann is delivering a level of expertise and resources that is unequaled in the industry. Our partnership is excellent because we share a commitment to provide the best medical marijuana possible to the patients in Illinois.” Feb 2015
http://americann.co/investor-relations/
Our purpose is to fuel the growth of the medical cannabis industry and eliminate barriers for our partners to succeed. We see a world that shifts from prohibition to regulation so that all patients have access to safe, regulated medical cannabis.
AmeriCann, Inc. is a registered, audited, publicly traded, and fully reporting company with corporate offices in Denver and Boston. The company is focused on bringing sustainability and efficiency to the design, construction and oversight of highly productive, energy efficient greenhouse cannabis cultivation and processing facilities.
AI
